Paradoxically, in some COVID-19 patients, the signs of hypercoagulability go together with apparent hypocoagulability detected by a prolonged prothrombin time, reduced clot growth rate in the thrombodynamics assay, and prolonged clotting time in TEG. This evidence concerns the gene F2 and thrombophilia.